# PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray

> **NCT05122260** · PHASE1 · COMPLETED · sponsor: **Kenneth Palmer** · enrollment: 18 (actual)

## Conditions studied

- COVID-19 Prevention

## Interventions

- **DRUG:** Q-Griffithsin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05122260
- **Lead sponsor:** Kenneth Palmer
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-11
- **Primary completion:** 2022-01-27
- **Final completion:** 2022-02-14
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05122260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05122260, "PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05122260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*